Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC37i
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
ASC37i is a once-monthly subcutaneous triple peptide agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR). Developed by Ascletis (歌礼生物科技), the drug is currently in the discovery phase for the treatment of obesity. By simultaneously activating these three metabolic pathways, ASC37i aims to provide superior weight loss efficacy and metabolic benefits compared to single or dual agonists. The once-monthly dosing schedule is designed to improve patient compliance and convenience.
- Other names
- ASC37iASC-37iASC 37i
02
Targets
Beyond the preview
Go deeper on ASC37i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC37i.